The Alzheimer’s Society of Canada estimates that approximately 500,000 Canadians are suffering from dementia, which can cost between $12 billion and $15 billion annually in direct and indirect costs. Researchers at the University of British Columbia in Canada recently discovered an effective treatment for Alzheimer’s disease (Progeria). By stimulating brain cells called microglia, the cells can swallow up the large amount of aging plaque that remains in the patient’s brain, thus laying the foundation for a treatment for Alzheimer’s disease. The researchers are working to replicate the simulation of human brain cell activity in the laboratory, which could be an effective treatment for Alzheimer’s disease. The team found that etiolated spots are not efficient microglial activators, but when microglia are covered with stimuli, they will actively attack the etiolated spots. Principal investigator Dr. Nakazawa said he was pleased to see microglia meeting and attaching to the etiolated spots under the microscope, just as the researchers had previously predicted. Microglia are located in the central nervous system and have the effect of immune cells in the brain. The human brain contains about 14 billion microglia, respectively “ cruising ” in various parts of the brain, for the damaged cells to restore their normal function to provide help. Dr. McKeel, professor emeritus at the University of British Columbia, said that amyloid deposits form erosions that are now widely recognized as the cause of Alzheimer’s disease. Alzheimer’s disease is a manifestation of neurological degeneration and disorganization, and its two most obvious pathological features are ectopia and neurofibrillary tangles. It has previously been theorized that it is the ectopia that damages the patient’s brain cells, leading to a decline in brain function and other symptoms. Microglia in Alzheimer’s patients do not intervene in the formation of erosions, so the rate of erosion aggregation is much higher than the rate at which microglia dissipate the erosions. If researchers can accelerate the rate at which microglia dissolve the erosions, this could be an important tool for curing Alzheimer’s disease. This study will contribute to the clinical treatment of Alzheimer’s disease in humans and will replace the previous mouse test model. Dr. McKeel also said that this is only the first step in the new treatment, and the next step will be to explore how to develop a small glial stimulating drug that can dissolve the etiolated plaques.